Boehringer Ingelheim USA Corporation

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

Reversal of Dabigatran Anticoagulant Effect With Idarucizumab

Phase 3

Completed

Conditions: Hemorrhage

Interventions: Drug: idarucizumab

First Posted Date: 2014-04-07

Last Posted Date: 2018-01-05

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 503

Registration Number: NCT02104947

Locations: 🇺🇸
IU Health Methodist Hospital, Indianapolis, Indiana, United States
🇺🇸
Duke University Medical Center, Durham, North Carolina, United States
🇺🇸
University of Cincinnati, Cincinnati, Ohio, United States

and more 173 locations

Bioavailability of Empagliflozin/Metformin Fixed Dose Combinations (FDCs) in Healthy Chinese Volunteers

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: 12.5 mg empagliflozin
Drug: 5 mg empagliflozin
Drug: 5 mg empagliflozin/850 mg metformin FDC
Drug: 5 mg empagliflozin/500 mg metformin FDC
Drug: 12.5 mg empagliflozin/500 mg metformin FDC
Drug: 500 mg metformin
Drug: 12.5 mg empagliflozin/850 mg metformin FDC
Drug: 850 mg metformin

First Posted Date: 2014-04-03

Last Posted Date: 2015-09-24

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 96

Registration Number: NCT02102932

Locations: 🇨🇳
1276.23.86002 Boehringer Ingelheim Investigational Site, Beijing, China

Combined Bronchodilators in Chronic Obstructive Pulmonary Disease and the Risk of Adverse Cardio-pulmonary Events

Completed

Conditions: Pulmonary Disease, Chronic Obstructive

First Posted Date: 2014-03-26

Last Posted Date: 2017-02-15

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 115397

Registration Number: NCT02096731

Locations: 🇨🇦
Boehringer Ingelheim Investigational Site, Montreal, Quebec, Canada

Bioequivalence of Two Transdermal Clonidine Administrations in Healthy Volunteers

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: Catapres-TTS-1

First Posted Date: 2014-03-26

Last Posted Date: 2015-07-16

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 56

Registration Number: NCT02096744

Locations: 🇺🇸
253.2486.1 Boehringer Ingelheim Investigational Site, Austin, Texas, United States

Afatinib in Subjects With Kidney Dysfunction

Phase 1

Completed

Conditions: Renal Insufficiency

Interventions: Drug: Afatinib moderate renally impaired
Drug: Afatinib severe renally impaired
Drug: Afatinib healthy

First Posted Date: 2014-03-26

Last Posted Date: 2016-01-14

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 30

Registration Number: NCT02096718

Locations: 🇩🇪
1200.216.1 Boehringer Ingelheim Investigational Site, Kiel, Germany

To Assess Safety, Tolerability and Pharmacokinetics of BI 416970 in Healthy Male Volunteers

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: Placebo to BI 416970
Drug: BI 416970

First Posted Date: 2014-03-21

Last Posted Date: 2016-03-22

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 60

Registration Number: NCT02093819

Locations: 🇩🇪
1345.1.1 Boehringer Ingelheim Investigational Site, Biberach, Germany

To Evaluate the Effect of Inhaled Medication Together With Exercise and Activity Training on Exercise Capacity and Daily Activities in Patients With Chronic Lung Disease With Obstruction of Airways

Phase 3

Completed

Conditions: Pulmonary Disease, Chronic Obstructive

Interventions: Drug: tiotropium +olodaterol
Drug: tiotropium
Drug: placebo to tiotropium + olodaterol
Drug: tiotropium+olodaterol

First Posted Date: 2014-03-12

Last Posted Date: 2017-01-06

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 304

Registration Number: NCT02085161

Locations: 🇬🇧
Boehringer Ingelheim Investigational Site, Sheffield, United Kingdom

Effectiveness and Safety of Different Doses of BI 1026706 in Patients With Postoperative Dental Pain

Phase 1

Completed

Conditions: Pain, Postoperative

Interventions: Drug: BI 1026706
Drug: Placebo to BI 1026706 solution
Drug: Celecoxib
Drug: Placebo to BI 1026706 tablet

First Posted Date: 2014-03-12

Last Posted Date: 2019-04-12

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 80

Registration Number: NCT02084511

Locations: 🇮🇹
1320.13.39001 Boehringer Ingelheim Investigational Site, Verona, Italy

Bioequivalence of a FDC Tablet of Linagliptin/Metformin (2.5mg/1000mg) Extended Release in Healthy Subjects.

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: Linagliptin
Drug: Metformin
Drug: Linagliptin/Metformin FDC

First Posted Date: 2014-03-11

Last Posted Date: 2016-08-04

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 74

Registration Number: NCT02084056

Locations: 🇩🇪
1288.11.1 Boehringer Ingelheim Investigational Site, Biberach, Germany

Bioequivalence of a FDC Tablet of Linagliptin/Metformin (5mg/1000mg) Extended Release in Healthy Subjects

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: Linagliptin/Metformin ER FDC
Drug: Linagliptin
Drug: Metformin ER

First Posted Date: 2014-03-11

Last Posted Date: 2016-08-04

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 68

Registration Number: NCT02084082

Locations: 🇩🇪
1288.9.1 Boehringer Ingelheim Investigational Site, Biberach, Germany

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy